Compare UA & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UA | CPRX |
|---|---|---|
| Founded | 1996 | 2002 |
| Country | United States | United States |
| Employees | 14400 | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.0B |
| IPO Year | N/A | 2006 |
| Metric | UA | CPRX |
|---|---|---|
| Price | $5.98 | $23.61 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | ★ 2.4M | 1.0M |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.24 |
| EPS | N/A | ★ 1.68 |
| Revenue | N/A | ★ $119,072,803.00 |
| Revenue This Year | N/A | $9.20 |
| Revenue Next Year | $1.72 | $10.51 |
| P/E Ratio | ★ N/A | $13.51 |
| Revenue Growth | N/A | ★ 16.39 |
| 52 Week Low | $3.95 | $19.05 |
| 52 Week High | $7.91 | $26.56 |
| Indicator | UA | CPRX |
|---|---|---|
| Relative Strength Index (RSI) | 40.53 | 49.38 |
| Support Level | $5.88 | $22.25 |
| Resistance Level | $6.44 | $24.94 |
| Average True Range (ATR) | 0.26 | 0.66 |
| MACD | -0.11 | -0.12 |
| Stochastic Oscillator | 22.63 | 45.57 |
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America, Asia-Pacific, Europe, and Latin America. Consumers of its performance-based clothing and shoes include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through wholesale partners, company-owned digital channels, and approximately 450 company-owned outlet and full-price stores. The Baltimore-based firm was founded in 1996 and is led by controlling shareholder Kevin Plank.
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.